For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Celldex Therapeutics Limited

USPTO Granted Patents = 45

CIPO Patents = 3

EPO Patents = 14

Trademarks = 3

Forward Citations = 148

Loading Chart...

Loading Chart...

78 inventors (with patents filed for the assignee):

Tibor P Keler (22 out of 40 patents)

Lizhen He (15 out of 15 patents)

Laura A Vitale (13 out of 15 patents)

4. Yaron R Hadari (8 out of 23 patents)

5. Lawrence J Thomas (8 out of 12 patents)

6. Joel Goldstein (7 out of 13 patents)

7. Henry C Marsh (6 out of 17 patents)

8. Venky Ramakrishna (6 out of 8 patents)

9. Elizabeth M Mandel-Bausch (6 out of 7 patents)

10. Francis Joseph Carr (5 out of 44 patents)

11. Timothy David Jones (5 out of 35 patents)

12. Tom O'Neill (4 out of 4 patents)

13. Andrea Crocker (4 out of 4 patents)

14. Karuna Sundarapandiyan (4 out of 5 patents)

15. Jenifer Widger (4 out of 4 patents)

Core Competencies:

Agonistic Antibodies

Anti-PD-1 Antibody

Chimeric Antigen Receptors

Bispecific Constructs

Anti-KIT Antibodies

Immune Response Enhancement

Polynucleotides Encoding Antibodies

Monoclonal Antibodies

Antibody Vaccine Conjugates

Dendritic Cells

Cancer Treatment

Eye Diseases Treatment

45 patents: Sort by Forward Citations

1. 12297266 - Agonistic antibodies that bind human CD40 and uses thereof (2025-05-13),

2. 11987626 - Treatment of eosinophil or mast cell related disorders (2024-05-21),

3. 11965031 - Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment (2024-04-23),

4. 11891452 - Anti-kit antibodies and uses thereof (2024-02-06),

5. 11884734 - Anti-MET antibodies and methods of use thereof (2024-01-30),

6. 11884699 - Anti-KIT antibodies and uses thereof (2024-01-30),

7. 11541076 - Chimeric antigen receptors targeting TIM-1 (2023-01-03),

8. 11459393 - Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs (2022-10-04),

9. 11332537 - Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs (2022-05-17),

10. 11180566 - Antibodies that bind human CD27 and uses thereof (2021-11-23),

11. 11091559 - Anti-ALK antibodies and methods for use thereof (2021-08-17),

12. 10941201 - Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies (2021-03-09),

13. 10865244 - Nucleic acids encoding agonistic antibodies that bind CD40 (2020-12-15),

14. 10793639 - Methods of treating by administering anti-kit antibodies (2020-10-06),

15. 10781267 - Methods of treating by administering anti-kit antibodies (2020-09-22),

Celldex Therapeutics Limited is a biotechnology company focused on the development and commercialization of immunotherapy and antibody-based therapeutics for the treatment of cancer. Their novel approach harnesses the power of the immune system to target and eliminate cancer cells. With a strong pipeline of innovative products and a commitment to improving patient outcomes, Celldex Therapeutics Limited is dedicated to advancing the field of oncology and finding effective treatments for patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

45 Patents

#22 in Cambridge

#385 in United Kingdom

#14,979 in the World

Cambridge, United Kingdom

Celldex Therapeutics Limited

Forward Citations = 148

78 inventors:

Tibor P Keler (22 out of 40 patents)

Lizhen He (15 out of 15 patents)

Laura A Vitale (13 out of 15 patents)

4. Yaron R Hadari (8 out of 23 patents)

5. Lawrence J Thomas (8 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…